- Home
- RLI vs CDTX Comparison
RLI vs CDTX Comparison
Compare RLI & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLI | CDTX |
|---|---|---|
| Founded | 1965 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.9B |
| IPO Year | 1985 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RLI | CDTX |
|---|---|---|
| Price | $64.14 | $220.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $72.80 | ★ $128.75 |
| AVG Volume (30 Days) | 867.7K | ★ 880.9K |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.82 | N/A |
| Revenue | ★ $1,855,871,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | $16.75 | ★ N/A |
| Revenue Growth | ★ 5.16 | N/A |
| 52 Week Low | $57.75 | $15.22 |
| 52 Week High | $83.20 | $221.20 |
Technical Indicators
Market Signals| Indicator | RLI | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.97 | 84.47 |
| Support Level | $64.32 | $220.40 |
| Resistance Level | $67.12 | $221.00 |
| Average True Range (ATR) | 1.12 | 0.47 |
| MACD | -0.13 | -3.46 |
| Stochastic Oscillator | 38.21 | 92.76 |
Price Performance
Historical ComparisonAbout RLI RLI Corp. (DE)
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.